In preemptive strike, Sanders, Cummings demand PTC chief Peltz spell out his price for controversial Duchenne MD treatment
It’s time for Stuart Peltz to take the Congressional hot seat on drug pricing.
The CEO of PTC Therapeutics acquired Marathon’s steroid deflazacort for $140 million up front a few days ago with an eye to sell it to a small population of Duchenne muscular dystrophy patients. And that comes with as much of a glaring spotlight as Senator Bernie Sanders and Rep. Elijah Cummings can bring to it.
In a new letter directed to Peltz, the two activist lawmakers noted in a preemptive strike that the CEO has been in touch with the Parent Project for Muscular Dystrophy to talk price. And they have a retail number in mind that PTC $PTCT won’t likely cotton to: The UK net price of $1,000 to $1,200 a month, which is what many parents are paying today.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.